Results 81 to 90 of about 29,210 (297)

Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK study

Blood Advances, 2023
Key Points • Ibrutinib ± rituximab was effective and well tolerated as first-line MCL therapy; outcomes were worse in patients with high-risk disease.• Novel approaches are needed for patients with high-risk MCL and those with progressive disease after ...
A. Tivey, R. Shotton, T. Eyre, D. Lewis, Louise Stanton, Rebecca Allchin, Harriet Walter, F. Miall, Rui Zhao, A. Santarsieri, R. McCulloch, M. Bishton, A. Beech, V. Willimott, Nicole Fowler, Claudia Bedford, Jack Goddard, Samuel Protheroe, Angharad Everden, D. Tucker, Joshua Wright, Srivasavi Dukka, Miriam Thomson, S. Paneesha, M. Prahladan, Andrew Hodson, I. Qureshi, M. Koppana, Mary Owen, Kushani Ediriwickrema, H. Marr, Jamie Wilson, Jonathan Lambert, D. Wrench, C. Burney, Chloe Knott, G. Talbot, A. Gibb, Angela Lord, Barry Jackson, Simon Stern, Taylor Sutton, Amy Caitlin Webb, Marketa Wilson, Nicky Thomas, J. Norman, E. Davies, Lisa Lowry, Jamie Maddox, N. Phillips, N. Crosbie, Marcin Flont, Emma Lm Nga, A. Virchis, R. Guerrero Camacho, Wunna Swe, Arvind R Pillai, Clare Rees, James Bailey, S. G. Jones, Susan Smith, F. Sharpley, C. Hildyard, S. Mohamedbhai, T. Nicholson, S. Moule, Anshuman Chaturvedi, K. Linton   +67 more
semanticscholar   +1 more source

Status of oncology drugs with a conditional approval: A cross‐sectional comparison of the Food and Drug Administration and Health Canada

British Journal of Clinical Pharmacology, EarlyView.
Aims This study looks at the status of the same drugs conditionally approved by the Food and Drug Administration and Health Canada for the same oncology indication. Methods Lists of oncology drugs with a conditional approval from the Food and Drug Administration and Health Canada were generated and drug pairs with the same indication were matched ...
Joel Lexchin
wiley   +1 more source

Development of a Partial Proteolysis Targeting Chimera Library Based on Achiral Cereblon E3 Ligase Ligands and its Application for Bruton's Tyrosine Kinase Degraders

ChemMedChem, EarlyView.
A partial proteolysis targeting chimera (PROTAC) library bearing achiral phenyl dihydrouracil cereblon ligands is prepared. It is then applied to the rapid development of a full PROTAC library targeting Bruton's tyrosine kinase, which can be directly used for screening.
Chelsi M. Almodóvar‐Rivera, Ira Tandon, Ramesh Mudududdla, Paulina N. Esguerra, Kevin Lucio‐Acero, Weiping Tang   +5 more
wiley   +1 more source

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia

Case Reports in Hematology, 2021
Ibrutinib is a targeted therapy drug that blocks the activity of Bruton’s tyrosine kinase, and it is an approved treatment for several mature B-cell malignancies including chronic lymphocytic leukaemia (CLL).
Sara Kristina Viberg Tjønnfjord, Eirik Brekka Tjønnfjord, Zbigniew Konopski, Geir Erland Tjønnfjord   +3 more
doaj   +1 more source

Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Ibrutinib and acalabrutinib are Bruton tyrosine kinase inhibitors used in the treatment of B‐cell lymphoproliferative disorders. Ibrutinib is associated with new‐onset atrial fibrillation.
Jari M. Tuomi, Loryn J. Bohne, Tristan W. Dorey, Hailey J. Jansen, Yingjie Liu, Douglas L. Jones, Robert A. Rose   +6 more
doaj   +1 more source

Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia

Blood Advances, 2023
Key Points • First comparative effectiveness study of acalabrutinib and ibrutinib in real-world patients with chronic lymphocytic leukemia.• Acalabrutinib demonstrated statistically significant longer time to discontinuation than ibrutinib.
L. Roeker, M. DerSarkissian, K. Ryan, Yan Chen, M. Duh, S. Wahlstrom, S. Hakre, Louise Yu, Helen Guo, A. Mato   +9 more
semanticscholar   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, EarlyView.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source

Ibrutinib and Venetoclax for First-Line Treatment of CLL.

New England Journal of Medicine, 2019
BACKGROUND Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL).
N. Jain, M. Keating, P. Thompson, A. Ferrajoli, J. Burger, G. Borthakur, Koichi Takahashi, Z. Estrov, N. Fowler, T. Kadia, M. Konopleva, Y. Alvarado, M. Yilmaz, C. DiNardo, P. Bose, M. Ohanian, N. Pemmaraju, E. Jabbour, K. Sasaki, R. Kanagal-Shamanna, K. Patel, J. Jorgensen, N. Garg, Xuemei Wang, K. Sondermann, Nichole D Cruz, Chongjuan Wei, A. Ayala, W. Plunkett, H. Kantarjian, V. Gandhi, W. Wierda   +31 more
semanticscholar   +1 more source

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

Cancers, 2023
Simple Summary Ibrutinib is an established standard of care in the first-line treatment of chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term treatment, outcomes, and safety are essential to inform clinical decision ...
J. Woyach, P. Barr, T. Kipps, J. Barrientos, I. Ahn, P. Ghia, Vincent Girardi, E. Hsu, Mandy Jermain, J. Burger   +9 more
semanticscholar   +1 more source